Uncategorized – Project Breathing Hope

A New Data Challenge Current Standard in Treating EGFR+ Lung Cancer

Post author:admin
Post published:November 5, 2019
Post category:Education Research Uncategorized

New Data Challenge Current Standard in Treating EGFR+ Lung Cancer Review of Commentary by Dr. Mark G. Kris, Memorial Sloan Kettering Cancer CenterSummary by Dr. Jennifer CiprianiNew Data Challenge Current…

New Data Challenge Current Standard in Treating EGFR+ Lung Cancer

Post author:admin
Post published:September 19, 2019
Post category:Education Research Uncategorized

https://www.medscape.com/viewarticle/917613?src=WNL_confwrap_190918_MSCPEDIT&uac=280951SX&impID=2098488&faf=1&fbclid=IwAR0s_0d3rxikKY0QY8_EPEsHGEFDVG0RH6G3OXyGflGFOftZ9F-RwSNpoLE New Data Challenge Current Standard in Treating EGFR+ Lung Cancer This transcript has been edited for clarity. This is Mark Kris from Memorial Sloan Kettering. Just when we thought…

• How many people? 155,000 Americans lose their lives to lung cancer each year. • The #1 killer. Lung cancer is the leading cancer killer of both men and women in the U.S. (second only to heart disease in overall cause of death) • Research funding needed. Lung cancer receives only $1,831 in federal research funds per death, compared to $4,582 for colorectal cancer and $13,406 for breast cancer. • Not just a “smokers’s disease.” Around 70% of lung cancer victims are never-smokers (100 or fewer cigarettes smoked over a lifetime1). • Women at greater risk. Lung cancer is the leading cause of cancer death in women, killing more women each year than breast cancer, uterine cancer, and ovarian cancer combined. Two-thirds of never-smokers who develop lung cancer are women. • Survival. Lung cancer currently has only a 5-year overall survival rate of 5-20%, shockingly low compared to the next three most common cancers (breast, prostate and colon), which now have 5-year survival rates approaching 80 – 90%, thanks to research funding. • Lack of early detection. 41% of patients diagnosed with non-small cell lung cancer (NSCLC) are not diagnosed until Stage IV.1 EGFR-Positive Lung Cancer • Prevalence. Around 15% of all lung cancer patients in the U.S. are diagnosed with EGFR-positive (EGFR+) lung cancer, with prevalence among people of Eastern Asian descent much higher, between 35 – 50%. • Never-smokers. Lung cancers in non-smokers and never-smokers are far more likely to express the EGFR+ mutation. • Populations at greatest risk. EGFR+ is more common among: never-smokers and non-smokers; women than men; people of East Asian heritage; Caucasians than African Americans; young adults. (Roughly 50% of young adults with lung cancer have EGFR mutations.) —————————————- 1. Lovly, C., L. Horn, W. Pao. 2015. EGFR in Non-Small Cell Lung Cancer (NSCLC). My Cancer Genome https://www.mycancergenome.org/content/disease/lung-cancer/egfr 2. Zhu QG, Zhang SM, Ding XX, He B, Zhang HQ. Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget. 2017;8(34):57680-57692. * Other sources of statistics include: American Cancer Society, National Cancer Institute.

See Jen's story on social media.

Helping to Rewrite the Future of Lung Cancer

See Jen's story on social media.

Helping to Rewrite the Future of Lung Cancer

A New Data Challenge Current Standard in Treating EGFR+ Lung Cancer

New Data Challenge Current Standard in Treating EGFR+ Lung Cancer

Project Breathing Hope

SHARE

Contact Project Breathing Hope Today

Help to Rewrite the Future of Lung Cancer

FOUNDATION

GET INVOLVED